1952 Stock Overview A biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Everest Medicines Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Everest Medicines Historical stock prices Current Share Price HK$46.50 52 Week High HK$52.15 52 Week Low HK$14.34 Beta 1.93 1 Month Change 20.00% 3 Month Change 86.75% 1 Year Change 151.08% 3 Year Change 32.10% 5 Year Change n/a Change since IPO -36.08%
Recent News & Updates
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients Dec 18
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Dec 17
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients Dec 12
New minor risk - Share price stability Dec 02
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong Dec 02
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List Nov 28 See more updates
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients Dec 18
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis Dec 17
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients Dec 12
New minor risk - Share price stability Dec 02
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong Dec 02
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List Nov 28
Everest Medicines Announces Two In Vitro Studies on Eravacycline (XERAVA) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity Nov 22
Now 27% overvalued after recent price rise Nov 20
Everest Medicines Announces NEFECON Receives Full Approval from South Korea's Ministry of Food and Drug Safety for the Treatment of Primary IgA Nephropathy Nov 19
Everest Medicines Limited Announces Business Update on NEFECON Development Oct 24
Now 21% undervalued Oct 15
Now 24% undervalued Sep 16
Consensus EPS estimates fall by 38%, revenue upgraded Sep 04
First half 2024 earnings: Revenues in line with analyst expectations Sep 01
Now 22% undervalued after recent price drop Aug 29
New minor risk - Profitability Aug 28
No longer forecast to breakeven Aug 28
Everest Medicines Limited to Report First Half, 2024 Results on Aug 27, 2024 Aug 05
Now 21% undervalued after recent price drop Jul 24
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis Jul 22
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration Jul 18
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis Jul 15
Everest Medicines Limited, Annual General Meeting, Jun 28, 2024 Jun 06
Now 24% overvalued after recent price rise May 22
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China May 15
Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau May 08
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients May 02
Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet? Apr 27
Now 22% overvalued after recent price rise Apr 26
Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year Mar 31
Full year 2023 earnings released Mar 30
Forecast to breakeven in 2026 Mar 28
Now 23% overvalued after recent price rise Mar 28
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer Mar 19
Consensus revenue estimates increase by 28% Mar 16
Everest Medicines Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 06
Now 25% overvalued after recent price rise Feb 29
Everest Medicines Limited Announces Board Changes Feb 09
Now 23% undervalued after recent price drop Feb 05
A Look At The Fair Value Of Everest Medicines Limited (HKG:1952) Jan 31
Consensus revenue estimates increase by 17% Jan 23
Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023 Jan 22
Everest Medicines Limited Announces Directorate Changes Jan 12
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients Dec 27 Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024 Nov 29
Calliditas’ Partner Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy Nov 27
National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China Nov 25
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy Oct 27
Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients Sep 28
Consensus revenue estimates decrease by 16%, EPS upgraded Sep 12
First half 2023 earnings released: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022) Aug 26
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy Aug 25
Everest Medicines Limited to Report First Half, 2023 Results on Aug 24, 2023 Aug 09
Everest Medicines Announces Completion of Patient Enrollment in Nefecon®? China Open Label Extension Study Aug 02
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China Jul 27
Everest Medicines Appoints Mike Berry as Chief Technology Officer Jun 16
New major risk - Share price stability Jun 16
Everest Medicines Limited, Annual General Meeting, Jun 29, 2023 May 31
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia May 17
Consensus revenue estimates increase by 151% May 09
Consensus revenue estimates decrease by 17% Apr 13
No longer forecast to breakeven Apr 04
Consensus estimates of losses per share improve by 91% Feb 24
Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary Iga Nephropathy Feb 10
Consensus EPS estimates fall by 593% Feb 10
Everest Medicines Limited Announces Board Changes Jan 20 Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China Jan 18
Consensus revenue estimates fall by 28% Jan 05
Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorization Application in 2023 in China for Its Lead mRNA Candidate Jan 04 Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone Dec 15
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy Nov 28
Less than half of directors are independent Nov 16
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy Nov 15
Everest Medicines Announces Approval of XERAVA in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections Oct 08
Forecast to breakeven in 2022 Sep 27
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001 Sep 26 Everest Medicines Appoints Rogers Yongqing Luo as an Executive Director Everest Medicines Limited Announces Resignation of Kerry Blanchard as A Member of the Board of Directors
Consensus revenue estimates increase by 99% Aug 18
Everest Medicines Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan Aug 11
Everest Medicines Announces Approval of Trodelvy in China for Second-Line Metastatic Triple-Negative Breast Cancer Jun 10
Less than half of directors are independent Apr 27
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis Apr 06
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan Mar 31
Forecast to breakeven in 2024 Mar 31 Everest Medicines Limited, Annual General Meeting, Jun 30, 2022 Mar 31
Forecast to breakeven in 2024 Mar 30 Everest Medicines Limited, Annual General Meeting, Jun 30, 2022 Mar 30
Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary Mar 29 Shareholder Returns 1952 HK Biotechs HK Market 7D -1.9% -3.9% -0.5% 1Y 151.1% -5.7% 19.9%
See full shareholder returns
Return vs Market: 1952 exceeded the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 1952's price volatile compared to industry and market? 1952 volatility 1952 Average Weekly Movement 13.6% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 1952's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1952's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company Everest Medicines Limited, a biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.
Show more Everest Medicines Limited Fundamentals Summary How do Everest Medicines's earnings and revenue compare to its market cap? 1952 fundamental statistics Market cap HK$14.95b Earnings (TTM ) -HK$1.12b Revenue (TTM ) HK$446.06m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1952 income statement (TTM ) Revenue CN¥418.55m Cost of Revenue CN¥101.53m Gross Profit CN¥317.02m Other Expenses CN¥1.37b Earnings -CN¥1.05b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -3.28 Gross Margin 75.74% Net Profit Margin -251.64% Debt/Equity Ratio 10.9%
How did 1952 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 23:53 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Everest Medicines Limited is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bo Li BofA Global Research Peng Zou China International Capital Corporation Limited Ziyu He China International Capital Corporation Limited
Show 11 more analysts 
